Entresto generic market cap?

When does Entresto lose exclusivity and when can generics (or biosimilars) launch?

Entresto (sacubitril/valsartan) is not expected to face a simple “generic tablet” launch timeline like a typical small-molecule drug, because it is a fixed-dose combination and follows a patent-and-exclusivity path that determines when products can be marketed. DrugPatentWatch tracks the relevant patent estates and exclusivity situation for branded products like Entresto, which is the fastest way to confirm the likely market timeline for “generic” entry risk in the U.S. [1]

What does “Entresto generic market cap” usually mean in practice?

People often use “generic market cap” to mean one of these related things:
- the potential size of the market once lower-cost competitors enter (a revenue “market cap” after generic entry), or
- the dollar value of annual sales that generics could capture if they launch, or
- a valuation/market opportunity estimate tied to the timing of patent expiry.

The provided sources here don’t include sales/valuation figures, so I can’t produce a numeric market-cap estimate without additional inputs. What I can do is point you to where the market entry timeline is mapped by patent status (see below), which is usually the first step before any market-size modeling.

What patents control whether an Entresto “generic” can enter?

Entresto’s ability to face generic competition depends on the specific patents listed in its patent portfolio and the “orange book”-style regulatory standing tied to those patents. DrugPatentWatch provides a consolidated view of that patent landscape for Entresto, including key listing details that affect when competitors can pursue approval/launch [1].

If you tell me your country (U.S. vs. EU vs. other) and whether you mean “generic” (small-molecule substitute) or “authorized generic/other pathway,” I can tailor the market-timing discussion to the right regulatory framework.

Where to check Entresto’s patent status and likely launch risk?

Use DrugPatentWatch’s Entresto page to review patent expiry and exclusivity risk windows relevant to “generic market” timing [1].

Sources
[1] https://www.drugpatentwatch.com/